The Securities and Exchange Commission (SEC) has filed a lawsuit against Bruce Cameron Conway accusing him of insider trading.

Bruce Cameron Conway is 74 years old and resides in Dallas County, Texas.

In its complaint, submitted at the Texas Northern District Court on August 7, 2025, the SEC alleges that, beginning on July 22, 2020, Conway committed insider trading when he purchased shares of Cancer Genetics, Inc. (“CGIX”) common stock, which was then a publicly traded company.

Conway purchased the stock on the basis of material nonpublic information obtained as part of his investment into a privately-held biotechnology company (“Private Biotech Company”) that planned to merge with CGIX.

Conway’s investment adviser approached him about a potential investment into Private Biotech Company. After agreeing to confidentiality terms, Conway learned that Private Biotech Company would merge into an unidentified NASDAQ-traded public company.

Within a week, Conway learned from his investment adviser that the public company was CGIX. He then purchased CGIX shares in fifteen accounts belonging to him, his wife, his daughter, his son, and other family-owned trust accounts.

When CGIX publicly announced the merger about one month later, its stock price increased by 215% from the previous day’s closing price, and that same day Conway began to sell CGIX shares. Conway’s illegal insider trading generated approximately $160,000 in trading profits across the fifteen accounts.

The SEC claims that by engaging in this conduct, Conway violated Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) [15 U.S.C. § 78j(b)], and Rule 10b-5 thereunder [17 C.F.R. § 240.10b-5], and unless restrained and enjoined, will continue to violate the federal securities laws.

The SEC seeks a final judgment: (a) permanently enjoining Defendant from violating the federal securities laws by engaging in the transactions, acts, practices, and courses of business alleged in this Complaint; (b) ordering Defendant to disgorge any ill-gotten gains he received with prejudgment interest thereon pursuant to Exchange Act Sections 21(d)(3), (5), and (7) [15 U.S.C. §§ 78u(d)(3), (5) and (7)]; and (c) ordering Defendant to pay civil money penalties pursuant to Exchange Act Section 21A [15 U.S.C. § 78u-1].

Conway asserted his Fifth Amendment rights against self-incrimination when asked about his purchase of CGIX shares during the SEC’s investigation.